<DOC>
	<DOC>NCT02652429</DOC>
	<brief_summary>An Open-Label Long-Term Safety Study of Inhaled Nitric Oxide (iNO) for Pulmonary Arterial Hypertension (PAH)</brief_summary>
	<brief_title>Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH</brief_title>
	<detailed_description>An open-label, long-term study to evaluate the safety of inhaled nitric oxide (iNO) in subjects with pulmonary arterial hypertension (PAH) who participated in IK-7001-PAH-201 and to provide these patients with continued access to chronic iNO until the time of approval or when the trial is discontinued due to lack of efficacy.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>Signed Informed Consent Form prior to the initiation of any study mandated procedures or assessments. PAH subjects who have completed all EOS assessments in IK7001PAH201 study and have continued drug/device usage until EOS. Subjects are willing and considered in the judgement of the Investigator able to use the INOpulse device for up to 24 hours per day and could benefit from continued use. All female subjects must be willing to continue to take adequate precaution to avoid pregnancy by using suitable methods of birth control. Subjects who require treatment with riociguat Subjects who early discontinued drug/device usage due to withdrawal of consent or an AE requiring termination from treatment in IK7001PAH201</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>PAH</keyword>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>Inhaled Nitric Oxide</keyword>
	<keyword>iNO</keyword>
</DOC>